UBS Upgrades Coherus Biosciences (CHRS) to Buy, 'Underappreciated growth narrative, cheap valuation'
Tweet Send to a Friend
UBS analyst Ashwani Verma upgraded Coherus Biosciences (NASDAQ: CHRS) from Neutral to Buy with a price target of $11.00.The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
